ALDHHigh Breast Cancer Stem Cells Exhibit a Mesenchymal–Senescent Hybrid Phenotype, with Elevated Metabolic and Migratory Activities
Cells · 2024
DOI: 10.3390/cells13242059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Luis Larrea Murillo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, Salford M5 4WT, UK. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Breast Neoplasms, Aldehyde Dehydrogenase, Cell Movement. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by research grant funding, provided by Lunella Biotech, Inc. (to F.S. and M.P.L.), Lunella Biotech, Inc..
Abstract (Originalsprache)
Cancer stem cells (CSCs) account for 0.01 to 2% of the total tumor mass; however, they play a key role in tumor progression, metastasis and resistance to current cancer therapies. The generation and maintenance of CSCs are usually linked to the epithelial–mesenchymal transition (EMT), a dynamic process involved in reprogramming cancer cells towards a more aggressive and motile phenotype with increased stemness potential. Cells that undergo an EMT process have shown to be more resistant to conventional chemo/radiotherapies. In this context, aldehyde dehydrogenase (ALDH) enzymes, known for their role in the cellular detoxification of aldehydes and enhancement of cell survival, are often upregulated in cancer cells, promoting their resistance to conventional cancer treatments. Indeed, high ALDH levels have become a hallmark biomarker of CSCs and are often used to isolate this sub-population from the more abundant cancer cell populations. Herein, we isolated human breast cancer epithelial cells with higher ALDH abundance (ALDHHigh) and compared them to those with low ALDH abundance (ALDHLow). ALDHHigh sub-populations exhibited more characteristic EMT biomarkers by adopting a more mesenchymal phenotype with increased stemness and enhanced migratory potential. Furthermore, ALDHHigh sub-populations displayed elevated senescent markers. Moreover, these cells also demonstrated higher levels of mitochondria DNA/mass, as well as greater mitochondrial and glycolytic metabolic function. Conversely, ALDHLow sub-populations showed a higher efficiency of mammosphere/colony formation and an increased proliferative capacity. Therefore, we demonstrated that these ALDH sub-populations have distinct characteristics, underscoring their role in EMT, the formation of tumors and the mechanisms of metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, Salford M5 4WT, UK.
- Lunella Biotech, 1145 Carling Avenue, Ottawa, ON K1Z 7K4, Canada.
ORCID-Profile: Luis Larrea Murillo, Ghada S Hassan
Förderung
- This work was supported by research grant funding, provided by Lunella Biotech, Inc. (to F.S. and M.P.L.)
- Lunella Biotech, Inc.
Zitieren
APA
Larrea Murillo, L., Sugden, C. J., Ozsvari, B., Moftakhar, Z., Hassan, G. S., Sotgia, F., & Lisanti, M. P. (2024). ALDHHigh Breast Cancer Stem Cells Exhibit a Mesenchymal–Senescent Hybrid Phenotype, with Elevated Metabolic and Migratory Activities. Cells. https://doi.org/10.3390/cells13242059
Vancouver
Larrea Murillo L, Sugden CJ, Ozsvari B, Moftakhar Z, Hassan GS, Sotgia F, et al. ALDHHigh Breast Cancer Stem Cells Exhibit a Mesenchymal–Senescent Hybrid Phenotype, with Elevated Metabolic and Migratory Activities. Cells. 2024. doi:10.3390/cells13242059
BibTeX
@article{LarreaMurillo2024,
author = {Larrea Murillo, Luis and Sugden, Conor J and Ozsvari, Bela and Moftakhar, Zahra and Hassan, Ghada S and Sotgia, Federica and Lisanti, Michael P},
title = {ALDHHigh Breast Cancer Stem Cells Exhibit a Mesenchymal–Senescent Hybrid Phenotype, with Elevated Metabolic and Migratory Activities},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13242059}
}
EUVIMED